# US 2006/0223863 A1 · Methods for treating Hepatitis C

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0223863 A1
- Document ID: US20060223863A1
- Status: Published application
- Kind: A1
- Application number: 11/180,961
- Filed: 2005-07-14
- Published: 2006-10-05
- Earliest claimed: 2004-07-14
- Assignees: PTC Therapeutics, Inc.
- Inventors: Gary Karp; Peter Hwang; James Takasugi; Hongyu Ren; Richard Wilde; Anthony Turpoff; Alexander Arefolov; Guangming Chen; Jeffrey Campbell
- Web page: https://patentgrep.com/patent/US20060223863A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

## Claims

### Claim 1

A pharmaceutical composition for the prevention or treatment of Hepatitis C viral (HCV) infection comprising a therapeutically effective amount of at least one compound having the following formula:
wherein:
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group;
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alkyl;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORl, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRoCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C1 to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORu group, where Ru is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry is a C1 to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NReeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above,
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient, and optionally one or more additional anti-HCV agent.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein said one or more additional anti-HCV agent is selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, a caspase inhibitor, a drug which targets inosine monophosphate dehydrogenase inhibitors (IMPDH), synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist and combinations thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein X is selected from the group consisting of -hydrogen; -a cyano group; and -a —CORa group, where Ra is: -a C1 to C6 alkyl, or -a dialkyl-amino.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein X is selected from the group consisting of cyano and a —CORa group, where Ra is -a dialkyl-amino.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein X is cyano.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein Y is selected from the group consisting of the following compounds:

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein Y is selected from the group consisting of the following compounds:

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is selected from the group consisting of -a hydrogen; -a C1 to C6 alkyl optionally substituted with: -an alkoxy, -one or more halogens, or -a C6 to C8 aryl; -a C2 to C6 alkylene; and -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is selected from the group consisting of a hydrogen; -a C1 to C6 alkyl optionally substituted with: -a C6 to C8 aryl; -a C2 to C6 alkylene; and -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein R is a hydrogen.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is selected from the group consisting of -a hydrogen; -a halogen; -a nitro group; -a 5 or 6 membered heterocycle; -an alkoxy optionally substituted with: -a C6 to C8 aryl; -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein R2 is selected from the group consisting of -a nitro group; -a hydrogen; -a halogen; -a hydroxy group; -a C1 to C6 alkyl group, optionally substituted with one or more halogens; -an alkoxy group optionally substituted with: -one or more halogens, -an —OCORx group, where Rx is as defined above, -a dialkyl-amino optionally substituted with an alkoxy, -a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl, or -a 5 or 6 membered heteroaryl group; -an amide group; and -a —NHSO2Rx group, where Rx is as defined above.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein R2 is selected from the group consisting of -a hydrogen; -a C1 to C6 alkyl group, optionally substituted with one or more halogens; -an alkoxy group optionally substituted with: -one or more halogens, -a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl, or -a 5 or 6 membered heteroaryl group.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein R3 is a hydrogen.

### Claim 15

A pharmaceutical composition for the treatment of Hepatitis C viral (HCV) infection comprising a therapeutically effective amount of one or more of the following compounds:
or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein said composition further comprises an additional anti-HCV agent selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, a drug which targets inosine monophosphate dehydrogenase inhibitors (IMPDH), synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist and combinations thereof.

### Claim 17

A method for treating a subject for a Hepatitis C viral (HCV) infection comprising administering to said subject a pharmaceutical composition comprising an HCV inhibitory amount of one or more compound having the following formula:
wherein:
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group;
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alkyl;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORl, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRoCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C1 to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORu group, where Ru is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry is a C1 to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NReeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above,
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
and/or a pharmaceutically acceptable salt thereof, together with a a pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

The method of claim 17, wherein said method further comprises administering one or more additional anti-HCV agent.

### Claim 19 (depends on 18)

The method of claim 18, wherein said one or more additional anti-HCV agent is selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, caspase inhibitor, a drug which targets inosine monophosphate dehydrogenase inhibitors (IMPDH), synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist and combinations thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein X is selected from the group consisting of -hydrogen; -a cyano group; and -a —CORa group, where Ra is: -a C1 to C6 alkyl, or -a dialkyl-amino.

### Claim 21 (depends on 17)

The method of claim 17, wherein X is selected from the group consisting of cyano and a —CORa group, where Ra is -a dialkyl-amino.

### Claim 22 (depends on 17)

The method of claim 17, wherein X is cyano.

### Claim 23 (depends on 17)

The method of claim 17, wherein Y is selected from the group consisting of the following compounds:

### Claim 24 (depends on 17)

The method of claim 17, wherein Y is selected from the group consisting of the following compounds:

### Claim 25 (depends on 17)

The method of claim 17, wherein Z is selected from the group consisting of -a hydrogen; -a C1 to C6 alkyl optionally substituted with: -an alkoxy, -one or more halogens, or -a C6 to C8 aryl; -a C2 to C6 alkylene; and -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 26 (depends on 17)

The method of claim 17, wherein Z is selected from the group consisting of -a hydrogen; -a C1 to C6 alkyl optionally substituted with: -a C6 to C8 aryl; -a C2 to C6 alkylene; and -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 27 (depends on 17)

The method of claim 17, wherein R is a hydrogen.

### Claim 28 (depends on 17)

The method of claim 17, wherein R1 is selected from the group consisting of -a hydrogen; -a halogen; -a nitro group; -a 5 or 6 membered heterocycle; -an alkoxy optionally substituted with: -a C6 to C8 aryl; -a C6 to C8 aryl optionally substituted with an alkoxy.

### Claim 29 (depends on 17)

The method of claim 17, wherein R2 is selected from the group consisting of -a nitro group; -a hydrogen; -a halogen; -a hydroxy group; -a C1 to C6 alkyl group, optionally substituted with one or more halogens; -an alkoxy group optionally substituted with: -one or more halogens, -an —OCORx group, where Rx is as defined above, -a dialkyl-amino optionally substituted with an alkoxy, -a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl, or -a 5 or 6 membered heteroaryl group; -an amide group; and -a —NHSO2Rx group, where Rx is as defined above.

### Claim 30 (depends on 17)

The method of claim 17, wherein R2 is selected from the group consisting of -a hydrogen; -a C1 to C6 alkyl group, optionally substituted with one or more halogens; -an alkoxy group optionally substituted with: -one or more halogens, -a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl, or -a 5 or 6 membered heteroaryl group.

### Claim 31 (depends on 17)

The method of claim 17, wherein R3 is a hydrogen.

### Claim 32 (depends on 17)

The method of claim 17, wherein said compound is selected from the following compounds:

### Claim 33 (depends on 17)

The method of claim 17, wherein said compound is selected from the following compounds:

### Claim 34

A method for treating or preventing infection by a virus in a subject, wherein said virus comprises a internal ribosome entry site (IRES), comprising administering to said subject a pharmaceutical composition comprising a viral inhibitory amount of one or more compound having the following formula:
wherein
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alky;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORl, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRoCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C1 to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORu group, where Ru is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry is a C1 to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NeeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above,
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.

### Claim 35 (depends on 34)

The method of claim 34, further comprising administering one or more additional anti-viral agent.

### Claim 36 (depends on 35)

The method of claim 35, wherein said one or more additional anti-viral agent is selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, a drug which targets inosine monophosphate dehydrogenase inhibitors (IMPDH), synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist, and combinations thereof.

### Claim 37

A pharmaceutical composition for affecting viral IRES activity in a subject infected with a virus, comprising one or more compound having the following formula:
wherein:
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group;
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alkyl;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORl, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C1 to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORx group, where R1 is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry is a C1 to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NReeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above,
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
and/or a pharmaceutically acceptable salt thereof, together with a compound known in the art to affect IRES activity and a pharmaceutically acceptable excipient.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein said compound known in the art to affect IRES activity affects IRES mediated translation of an ORF encoding the polyprotein.

### Claim 39

A method for affecting viral IRES activity in a subject infected with a virus, comprising administering to said subject one or more compound having the following formula:
wherein:
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group;
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alkyl;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORl, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRoCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C, to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORu group, where Ru is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NReeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
and/or a pharmaceutically acceptable salt thereof, together with a compound known in the art to affect IRES activity and a pharmaceutically acceptable excipient.

### Claim 40 (depends on 39)

The method of claim 39, wherein said compound known in the art to affect IRES activity affects IRES mediated translation of an ORF encoding the polyprotein.

### Claim 41

A pharmaceutical composition for affecting viral IRES activity in a subject infected with a virus, comprising one or more compound having the following formulas, in an amount effective for affecting viral IRES activity:
wherein:
X is:
hydrogen;
a nitro group;
a cyano group;
a —CORa group, where Ra is:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or a halogen, or
a dialkyl-amino;
a —COORx group, where Rx is a C1 to C6 alkyl;
a formyl group;
a C6 to C8 aryl optionally substituted with an alkoxy; or
a 5 or 6-membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a C6 to C8 aryl optionally substituted with an alkoxy or one or more halogens, or
a 5 to 6 membered heteroaryl;
Y is:
a hydrogen;
a haloalkyl;
a halogen;
an amino optionally substituted with one or more C1 to C6 alkyls;
a benzofuran;
a benzothiophene;
a dibenzofuran;
a dibenzothiophene;
a benzothiazole;
a naphthalene;
an indole, optionally substituted on the nitrogen with a C1 to C6 alkyl;
where Rb is a hydrogen or a C1 to C6 alkyl, and n is 0 or 1;
where Rc is a hydrogen, a —CONHRx, where Rx is as defined above, or an —SO2Rx, where Rx is as defined above; or
where Rd is a C1 to C6 alkyl or a C6 to C8 aryl;
a —NHCORe group, where Re is:
a C1 to C6 alkyl;
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
an alkoxy,
a cyano group,
a nitro group, or
a halogen;
a —NHCOORx group, where Rx is as defined above;
a —CH2O—Rf group, where Rf is a C6 to C8 aryl;
a —NRgRh group, where Rg is a C1 to C6 alkyl or a hydrogen and Rh is a C6 to C8 aryl optionally substituted with an alkoxy;
a C1 to C6 alkyl;
a 5 or 6 membered heteroaryl, optionally substituted with:
a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a C6 to C8 aryl, optionally substituted with —COORx, where Rx is as defined above, or
an amino group;
a 5 or 6 membered heterocycle optionally substituted with:
a —COORx group, where Rx is as defined above, or
a —NHCOORx group, where Rx is as defined above;
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy, optionally substituted with:
an alkoxy,
a hydroxy,
one or more halogens,
a 5 or 6 membered heterocycle, optionally substituted with:
a C1 to C6 alkyl, or
a hydroxy,
an amino group optionally substituted with one or more C1 to C6 alkyls,
a —NRiSO2Rx group, where Rx is as defined above and Ri is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRjCORk group, where Rk is:
a C1 to C6 alkyl,
a hydrogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
and Rj is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —N═N+═N− group, or
a —CORx, where Rl is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,
an amino optionally substituted with one or more C1 to C6 alkyls,
a nitro group,
a C1 to C6 alkyl group, optionally substituted with:
a —NHSO2Rx group, where Rx is as defined above, or
a —NRxSO2Rx group, where Rx is as defined above,
a haloalkoxy,
a halogen,
a hydroxy,
a —COORx group, where Rx is as defined above,
a —CORm group, where Rm is:
an amino optionally substituted with one or more C1 to C6 alkyls, where the C1 to C6 alkyls are optionally substituted with:
a hydroxy
a 5 or 6 membered heterocycle,
an amino optionally substituted with one or more C1 to C6 alkyls,
an alkoxy,
a 3 to 7 membered heterocycle, optionally substituted with a C1 to C6 alkyl, optionally substituted with a dialkyl-amino,
a —NHRn group, where Rn is:
a —CH2CONH2, or
a C6 to C8 aryl optionally substituted with:
an alkyl,
one or more halogens,
a nitro group, or
one or more alkoxys,
a —NRoCORp group, where Rp is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
an alkoxy, or
a C6 to C8 aryl,
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with a halogen,
a 5 or 6 membered heteroaryl optionally substituted with one or more C1 to C6 alkyls,
a hydrogen,
and where Ro is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRqCONRqRr group, where Rq is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
and where Rr is:
a C6 to C8 aryl optionally substituted with:
a C1 to C6 alkyl,
a haloalkyl,
a —ORs group, where Rs is a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a C1 to C6 alkyl optionally substituted with one or more of the following:
a halogen,
an alkylene,
a C6 to C8 aryl, or
a —COORx group, where Rx is as defined above,
a —COORx group, where Rx is as defined above,
a —NRtCOORu group, where Ru is:
a C1 to C12 alkyl, optionally substituted with:
a C6 to C8 aryl optionally substituted with a C1 to C6 alkyl or an alkoxy,
an alkylene,
an alkoxy,
an alkyne,
a halogen, or
a 5 or 6 membered heterocycle,
a C6 to C8 aryl, optionally substituted with:
an alkoxy,
a halogen, or
a C1 to C6 alkyl, or
a 5 or 6 membered heterocycle,
and Rt is:
a hydrogen,
a C1 to C6 alkyl,
a —CORx group, where Rx is as defined above,
a haloalkyl, or
a haloalkoxy,
a —NRvSO2Rw group, where Rv is:
a hydrogen,
a —CORx, where Rx is as defined above, or
a C1 to C6 alkyl, optionally substituted with:
a halogen,
a —CORx group, where Rx is as defined above,
a —OCORx group, where Rx is as defined above,
a hydroxyl,
a hydroxyl, or
an alkoxy,
and where Rw is:
a C1 to C6 alkyl optionally substituted with:
a halogen,
a haloalkyl,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle,
a C2 to C6 alkylene,
an alkyl- or dialkyl-amino optionally substituted with a halogen,
a 5 or 6 membered heterocycle, or
a 5 or 6 membered heteroaryl optionally substituted with:
a C1 to C6 alkyl,
a 5 or 6 membered heterocycle, or
optionally substituted with a C1 to C6 alkyl, where Ry is a C1 to C6 alkyl or hydrogen,
where Rz is hydrogen or a C1 to C6 alkyl, optionally substituted with a C6 to C8 aryl,
a —SRx group, where Rx is as defined above,
a —SO2Raa group, where Raa is:
a C1 to C6 alkyl,
an amino group,
an alkyl- or dialkyl-amino group optionally substituted with a hydroxy or a —COORx group, where Rx is as defined above,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, or
a —NHRbb group, where Rbb is:
a —C(═S)NH2 group, or
a —PO(ORx)2, where Rx is as defined above;
group, where Rcc is:
a naphthalene,
a 5 or 6 membered heteroaryl,
a C6 to C8 aryl, optionally substituted with one or more of the following:
an alkoxy,
an hydroxy,
a halogen,
a C1 to C6 alkyl, optionally substituted with a cyano group,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NHPORxRx, where Rx is as defined above,
a —NReeCONRffRff group, where Ree is a hydrogen or a C1 to C6 alkyl, optionally substituted with a halogen, and Rff is:
a hydrogen,
a haloalkyl,
a haloalkoxy,
a C1 to C6 alkyl, or
a —CORx, where Rx is as defined above,
a —NRggCORhh group, where Rhh is:
a hydrogen,
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
a halogen, or
an amino optionally substituted with one or more C1 to C6 alkyls,
an amino optionally substituted with one or more C1 to C6 alkyls, where the alkyls are optionally substituted with a halogen,
a 5 or 6 membered heterocycle,
a 5 or 6 membered heteroaryl,
and Rgg is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy, or
a —CORx group, where Rx is as defined above,
a haloalkyl,
5 or 6 membered heterocycle groups,
an amino optionally substituted with one or more C1 to C6 alkyls,
a —NRiiSO2Rx group, where Rx is as defined above, and Rii is:
a hydrogen,
a C1 to C6 alkyl,
a haloalkyl,
a haloalkoxy,
a —CORx group, where Rx is as defined above;
Z is:
a hydrogen;
a C1 to C6 alkyl optionally substituted with:
an alkoxy,
one or more halogens, or
a C6 to C8 aryl;
a C2 to C6 alkylene;
a C6 to C8 aryl optionally substituted with an alkoxy or one or more C1 to C6 alkyls;
a —COORx group, where Rx is as defined above; or
R is a hydrogen, a halogen or an alkoxy;
R1 is:
a hydrogen;
a hydroxy;
a halogen;
a haloalkyl;
a nitro group;
a 5 or 6 membered heteroaryl;
a 5 or 6 membered heterocycle;
an alkoxy optionally substituted with:
one or more halogens,
a C6 to C8 aryl, or
a 5 or 6 membered heterocycle;
a C6 to C8 aryl optionally substituted with an alkoxy;
a —CORx group, where Rx is as defined above;
a C1 to C6 alkyl optionally substituted with a dialkyl-amino or a 5 or 6 membered heterocycle; or
R1 joins together with R2 to form:
R2 is:
a nitro group;
a hydrogen;
a halogen;
a hydroxy group;
a C1 to C6 alkyl group, optionally substituted with one or more halogens;
an amino group;
an alkoxy group optionally substituted with:
one or more halogens,
an —OCORx group, where Rx is as defined above
a dialkyl-amino optionally substituted with an alkoxy,
a 5 or 6 membered heterocycle group optionally substituted with a C1 to C6 alkyl,
a 5 or 6 membered heteroaryl group, or
a C6 to C8 aryl group;
a —COORx group, where Rx is as defined above;
a haloalkyl;
an amide group optionally substituted with:
a hydroxy group, or
a C6 to C8 aryl;
a 5 or 6 membered heteroaryl;
a —OCORx group, where Rx is as defined above;
a —NHCORjj group, where Rjj is:
an alkoxy, or
an amino optionally substituted with one or more C1 to C6 alkyls;
a —ORkk group, where Rkk is a 5 to 6 membered heteroaryl;
a —NHSO2Rx group, where Rx is as defined above; or
R2 joins together with R1 to form:
R3 is:
a hydrogen; or
CH2OCORx, and Rx is as defined above;
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
